BARRX Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BARRX Medical, Inc.
Acceleron/Celgene’s drug was effective across all endpoints in transfusion-dependent beta-thalassemia and myelodysplastic syndromes, but Acceleron CEO Habib Dable notes key secondary endpoints could be most meaningful to doctors treating these patients.
The week's round-up includes a new CEO at Synthorx Inc., new sales executives at Aerie Pharmaceuticals and board appointments at BTG, Pertinax Pharma, Realm Therapeutics, Breath Therapeutics, iOnctura, NBE Therapeutics and Inflazome.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced April-May 2016.